NDA 021124 · Karo Hlthcare
Lamisil At
Terbinafine Hydrochloride · Topical
Last checked: Nov 19, 2026Latest source record: Jul 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Mar 17, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
14 Phase 3, 3 recruiting
FAERS reports
1,412
890 serious, 54 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 12, 2025.
Uses • cures most athlete’s foot (tinea pedis) between the toes. Effectiveness on the bottom or sides of foot is unknown. • cures most jock itch (tinea cruris) and ringworm (tinea corporis) • relieves itching, burning, cracking and scaling which accompany these conditions
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- LAMISIL AT · TERBINAFINE HYDROCHLORIDE 1% · SOLUTION, TOPICAL · Over-the-counter
- LAMISIL AT · TERBINAFINE HYDROCHLORIDE 1% · SPRAY, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Terbinafine" as an intervention, any sponsor and status, largest first.
- Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail OnychomycosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00459537 · 1,029 participants · Start Mar 2007 · Primary completion Jan 2009
Drug: terbinafine hydrogen chloride; amorolfine nail lacquer · For: Onychomycosis
Sites: Various Cities, Finland; Various Cities, France; Various Cities, Germany · 10 sites in all
- TDT 067 Onychomycosis StudyPivotal-lookingStatus unknown
Celtic Pharma Development ServicesIndustry
NCT01145807 · 738 participants (planned) · Start Apr 2010 · Primary completion Feb 2012
Drug: TDT067; Placebo and 1 more · For: Onychomycosis
Sites: Albequerque, New Mexico
- Terbinafine Compared to Griseofulvin in Children With Tinea CapitisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00117754 · 720 participants · Start Jul 2004
Drug: Terbinafine hydrochloride · For: Tinea Capitis
Sites: East Hanover, New Jersey
- Terbinafine Compared to Griseofulvin in Children With Tinea CapitisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00117767 · 720 participants · Start Jun 2004 · Primary completion Mar 2006
Drug: Terbinafine hydrochloride (HCl); Griseofulvin · For: Tinea Capitis
Sites: East Hanover, New Jersey
- Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big ToenailPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00443820 · 526 participants · Start Dec 2006 · Primary completion Jun 2008
Drug: terbinafine; Placebo and 2 more · For: Onychomycosis
Sites: Novato, California; Northglenn, Colorado; Melbourne, Florida · 23 sites in all
- Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big ToenailPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00443898 · 518 participants · Start Dec 2006 · Primary completion Jun 2008
Drug: terbinafine; Placebo and 2 more · For: Onychomycosis
Sites: Birmingham, Alabama; San Diego, California; Denver, Colorado · 22 sites in all
- A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)Pivotal-lookingCompleted
Moberg Pharma ABIndustry
NCT02859519 · 365 participants · Start Oct 2016 · Primary completion Nov 13, 2019
Drug: MOB015B; MOB015B Vehicle · For: Distal Subungual Onychomycosis
Sites: Multiple Locations, California; Multiple Locations, Florida; Multiple Locations, Idaho · 10 sites in all
- A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)Pivotal-lookingStatus unknown
Moberg Pharma ABIndustry
NCT05279846 · 350 participants (planned) · Start May 9, 2022 · Primary completion Jan 2025
Drug: MOB015B; Vehicle (Placebo Comparator) · For: Onychomycosis
Sites: Birmingham, Alabama; Encinitas, California; Fremont, California · 35 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective121
- pruritus87
- rash82
- nausea75
- pain67
- fatigue66
- dyspnoea59
- off label use59
- diarrhoea53
- ageusia51
- headache50
- weight decreased50
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 30 |
| 2008 | 33 |
| 2009 | 20 |
| 2010 | 30 |
| 2011 | 26 |
| 2012 | 41 |
| 2013 | 16 |
| 2014 | 17 |
| 2015 | 58 |
| 2016 | 46 |
| 2017 | 55 |
| 2018 | 63 |
| 2019 | 80 |
| 2020 | 75 |
| 2021 | 86 |
| 2022 | 155 |
| 2023 | 154 |
| 2024 | 173 |
| 2025 | 160 |
| 2026 | 90 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- Seborrhoeic dermatitis.
Naldi L · BMJ Clin Evid 2010 · Systematic Review
- Seborrhoeic dermatitis.
Manríquez JJ, Uribe P · BMJ Clin Evid 2007 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2014 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2008 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Karo Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.